Chugai Pharmaceutical Co., Ltd. (TYO:4519)

Market Cap	11.50T +8.6%
Revenue (ttm)	1.34T +12.3%
Net Income	471.37B +19.2%
EPS	286.42 +19.2%
Shares Out	1.65B
PE Ratio	24.39
Forward PE	21.00
Dividend	132.00 (1.88%)
Ex-Dividend Date	Dec 29, 2026

Volume	1,196,300
Open	7,030.00
Previous Close	7,011.00
Day's Range	6,966.00 - 7,130.00
52-Week Range	6,002.00 - 10,700.00
Beta	0.55
Analysts	Buy
Price Target	9,350.00 (+33.82%)
Earnings Date	Oct 27, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,104
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4519

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.

Analyst Summary

According to 15 analysts, the average rating for 4519 stock is "Buy." The 12-month stock price target is ¥9,350, which is an increase of 33.82% from the latest price.

Price Target

¥9,350

(33.82% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 24, 2026

Data Sources Report a data error